ECSP11010869A - Combinación farmacéutica 3-(3-dimetilamino-1-etil-2-metil-propil)-fenol y un antiepiléptico - Google Patents

Combinación farmacéutica 3-(3-dimetilamino-1-etil-2-metil-propil)-fenol y un antiepiléptico

Info

Publication number
ECSP11010869A
ECSP11010869A EC2011010869A ECSP11010869A ECSP11010869A EC SP11010869 A ECSP11010869 A EC SP11010869A EC 2011010869 A EC2011010869 A EC 2011010869A EC SP11010869 A ECSP11010869 A EC SP11010869A EC SP11010869 A ECSP11010869 A EC SP11010869A
Authority
EC
Ecuador
Prior art keywords
antiepileptic
methyl
component
phenol
propil
Prior art date
Application number
EC2011010869A
Other languages
English (en)
Spanish (es)
Inventor
Thomas Christoph
Klaus Schiene
Funke Petra Blows
Original Assignee
Gruenenthal Chemie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40345058&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP11010869(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gruenenthal Chemie filed Critical Gruenenthal Chemie
Publication of ECSP11010869A publication Critical patent/ECSP11010869A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
EC2011010869A 2008-09-05 2011-03-04 Combinación farmacéutica 3-(3-dimetilamino-1-etil-2-metil-propil)-fenol y un antiepiléptico ECSP11010869A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP08015625 2008-09-05

Publications (1)

Publication Number Publication Date
ECSP11010869A true ECSP11010869A (es) 2011-04-29

Family

ID=40345058

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2011010869A ECSP11010869A (es) 2008-09-05 2011-03-04 Combinación farmacéutica 3-(3-dimetilamino-1-etil-2-metil-propil)-fenol y un antiepiléptico

Country Status (28)

Country Link
US (1) US20100063148A1 (enExample)
EP (2) EP2735338B1 (enExample)
JP (4) JP5731387B2 (enExample)
KR (3) KR101730924B1 (enExample)
CN (2) CN105520924B (enExample)
AR (2) AR073361A1 (enExample)
AU (3) AU2009289776A1 (enExample)
BR (1) BRPI0920521A2 (enExample)
CA (1) CA2735857C (enExample)
CL (1) CL2011000317A1 (enExample)
CO (1) CO6382142A2 (enExample)
CY (2) CY1115751T1 (enExample)
DK (2) DK2735338T3 (enExample)
EC (1) ECSP11010869A (enExample)
ES (2) ES2513394T3 (enExample)
HR (2) HRP20140663T1 (enExample)
HU (1) HUE043278T2 (enExample)
IL (3) IL211135A (enExample)
LT (1) LT2735338T (enExample)
MX (1) MX2011002339A (enExample)
PE (5) PE20142371A1 (enExample)
PL (2) PL2331210T3 (enExample)
PT (2) PT2735338T (enExample)
RU (2) RU2571501C2 (enExample)
SI (2) SI2735338T1 (enExample)
TR (1) TR201904388T4 (enExample)
WO (1) WO2010025931A2 (enExample)
ZA (1) ZA201101449B (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI312285B (en) 2001-10-25 2009-07-21 Depomed Inc Methods of treatment using a gastric retained gabapentin dosage
US20060159743A1 (en) * 2001-10-25 2006-07-20 Depomed, Inc. Methods of treating non-nociceptive pain states with gastric retentive gabapentin
US7612112B2 (en) 2001-10-25 2009-11-03 Depomed, Inc. Methods of treatment using a gastric retained gabapentin dosage
US20090176882A1 (en) 2008-12-09 2009-07-09 Depomed, Inc. Gastric retentive gabapentin dosage forms and methods for using same
CN102846601B (zh) 2006-06-15 2015-04-29 优时比制药有限公司 具有协同抗惊厥作用的药物组合物
US20100190752A1 (en) 2008-09-05 2010-07-29 Gruenenthal Gmbh Pharmaceutical Combination
WO2010025931A2 (en) * 2008-09-05 2010-03-11 Grünenthal GmbH Pharmaceutical combination
FR2943246B1 (fr) * 2009-03-19 2011-07-29 Biocodex Compose pour son utilisation dans le traitement des neuropathies peripheriques
KR101831616B1 (ko) * 2010-06-15 2018-04-04 그뤼넨탈 게엠베하 통증 치료용 약제학적 병용물
BR112013000190A2 (pt) 2010-07-06 2017-11-07 Gruenenthal Gmbh formas de dosagem de retenção gástrica compreendendo um análogo de gaba e um opioide
WO2012015027A1 (ja) 2010-07-30 2012-02-02 東レ株式会社 神経障害性疼痛の治療剤又は予防剤
KR101970468B1 (ko) * 2011-03-04 2019-04-19 그뤼넨탈 게엠베하 타펜타돌의 비경구 투여
US11413239B2 (en) * 2011-07-20 2022-08-16 Torrent Pharmaceuticals Ltd. Pharmaceutical composition of tapentadol for nasal administration
PL2736501T3 (pl) * 2011-07-29 2018-06-29 Grünenthal GmbH Dooponowe lub nadtwardówkowe podawanie 3-[(1S,2S)-3-(dimetyloamino)-1-etylo-2-metylopropylo]fenolu
US20130310385A1 (en) 2012-05-18 2013-11-21 Gruenenthal Gmbh Pharmaceutical Composition Comprising (1r,4r)-6'-fluoro-N,N-dimethyl-4-phenyl-4',9'-dihydro-3'H-spiro[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine and Antidepressants
US9320725B2 (en) 2012-05-18 2016-04-26 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r)-6′-fluoro-N,N-dimethyl-4-phenyl-4′9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine and a gabapentinoid
US9345689B2 (en) * 2012-05-18 2016-05-24 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r)-6′-fluoro-N, N-dimethyl-4-phenyl-4,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine and an anticonvulsant
US9320729B2 (en) 2012-05-18 2016-04-26 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r)-6′-flouro-N,N-dimethyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano-[3,4,b]indol]-4-amine and a propionic acid derivative
US9855286B2 (en) 2012-05-18 2018-01-02 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r)-6′-fluoro-N,N-di methyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano-[3,4,b]indol]-4-amine and a salicylic acid component
US20130310435A1 (en) * 2012-05-18 2013-11-21 Gruenenthal Gmbh Pharmaceutical Composition Comprising (1r,4r)-6'-fluoro-N, N-dimethyl-4-phenyl-4,9' -dihydro-3'H-spiro[cyclohexane-1,1' -pyrano[3,4,b]indol]-4-amine and Paracetamol or Propacetamol
US8912226B2 (en) * 2012-05-18 2014-12-16 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r) -6′-fluoro-N,N-dimethyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine and a NSAR
US9308196B2 (en) * 2012-05-18 2016-04-12 Gruenenthal Gmbh Pharmaceutical composition comprising (1 r,4r) -6'-fluoro-N ,N-dimethyl-4-phenyl-4',9'-d ihydro-3'H-spiro[cyclohexane-1,1'-pyrano-[3,4,b]indol]-4-amine and an oxicam
US9629818B2 (en) * 2012-11-01 2017-04-25 Torrent Pharmaceuticals Ltd. Pharmaceutical composition of tapentadol for parenteral administration
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
US9549909B2 (en) 2013-05-03 2017-01-24 The Katholieke Universiteit Leuven Method for the treatment of dravet syndrome
CN103655523A (zh) * 2013-12-24 2014-03-26 南京艾德凯腾生物医药有限责任公司 他喷他多组合物
KR20180095674A (ko) 2015-12-22 2018-08-27 조게닉스 인터내셔널 리미티드 대사 저항성 펜플루라민 유사체 및 그 사용 방법
SG11201804811WA (en) 2015-12-22 2018-07-30 Zogenix International Ltd Fenfluramine compositions and methods of preparing the same
RU2746000C2 (ru) 2016-08-24 2021-04-05 Зодженикс Интернэшнл Лимитед Состав для ингибирования образования агонистов 5-ht2b и способы его применения
US10682317B2 (en) 2017-09-26 2020-06-16 Zogenix International Limited Ketogenic diet compatible fenfluramine formulation
KR20190081385A (ko) 2017-12-29 2019-07-09 강원대학교산학협력단 옥스카바제핀을 유효성분으로 함유하는 허혈성 뇌혈관 질환 예방용 조성물
JP2021526507A (ja) 2018-05-11 2021-10-07 ゾゲニクス インターナショナル リミテッド 発作により誘発される突然死を処置するための組成物および方法
US12144787B2 (en) 2018-11-19 2024-11-19 Zogenix International Limited Method of treating patients with a mutation in cyclin-dependent kinase-like 5 (CDKL5)
US11612574B2 (en) 2020-07-17 2023-03-28 Zogenix International Limited Method of treating patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4389393A (en) 1982-03-26 1983-06-21 Forest Laboratories, Inc. Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose
US4765989A (en) 1983-05-11 1988-08-23 Alza Corporation Osmotic device for administering certain drugs
US4612008A (en) 1983-05-11 1986-09-16 Alza Corporation Osmotic device with dual thermodynamic activity
US4783337A (en) 1983-05-11 1988-11-08 Alza Corporation Osmotic system comprising plurality of members for dispensing drug
US5472711A (en) 1992-07-30 1995-12-05 Edward Mendell Co., Inc. Agglomerated hydrophilic complexes with multi-phasic release characteristics
US5330761A (en) 1993-01-29 1994-07-19 Edward Mendell Co. Inc. Bioadhesive tablet for non-systemic use products
US5455046A (en) 1993-09-09 1995-10-03 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems for insoluble drugs
US5399362A (en) 1994-04-25 1995-03-21 Edward Mendell Co., Inc. Once-a-day metoprolol oral dosage form
DE4426245A1 (de) 1994-07-23 1996-02-22 Gruenenthal Gmbh 1-Phenyl-3-dimethylamino-propanverbindungen mit pharmakologischer Wirkung
EA006598B1 (ru) * 1999-08-20 2006-02-24 Орто-Макнейл Фармасьютикал, Инк. Композиция, содержащая трамадол и противосудорожное лекарственное средство
CA2473536A1 (en) * 2002-01-16 2003-07-31 Endo Pharmaceuticals, Inc. Pharmaceutical composition and method for treating disorders of the central nervous system
WO2003070237A1 (en) * 2002-02-22 2003-08-28 Warner-Lambert Company Llc Combinations of an alpha-2-delta ligand with a selective inhibitor of cyclooxygenase-2
WO2007005716A2 (en) * 2005-06-30 2007-01-11 Cinergen, Llc Methods of treatment and compositions for use thereof
US20090082466A1 (en) * 2006-01-27 2009-03-26 Najib Babul Abuse Resistant and Extended Release Formulations and Method of Use Thereof
CN102671195B (zh) * 2006-04-28 2016-01-20 格吕伦塔尔有限公司 包含3-(3-二甲基氨基-1-乙基-2-甲基-丙基)-苯酚和nsaid的药物组合物
WO2008027442A2 (en) * 2006-08-30 2008-03-06 Theraquest Biosciences, Llc Abuse deterrent oral pharmaceutical formulations of opioid agonists and method of use
PL2596784T3 (pl) * 2007-11-23 2017-06-30 Grünenthal GmbH Kompozycje tapentadolu
TWI380812B (zh) * 2008-01-25 2013-01-01 Xenoport Inc （３ｓ）-胺甲基-５-甲基己酸前藥之晶形及使用方法
WO2010025931A2 (en) * 2008-09-05 2010-03-11 Grünenthal GmbH Pharmaceutical combination

Also Published As

Publication number Publication date
PE20190914A1 (es) 2019-06-26
RU2571501C2 (ru) 2015-12-20
AU2009289776A1 (en) 2010-03-11
CA2735857C (en) 2019-05-28
RU2011112444A (ru) 2012-10-10
HK1198145A1 (en) 2015-03-13
AU2018202879B2 (en) 2020-03-12
PL2735338T3 (pl) 2019-07-31
CY1115751T1 (el) 2017-01-25
EP2735338A1 (en) 2014-05-28
TR201904388T4 (tr) 2019-05-21
RU2674150C1 (ru) 2018-12-05
MX2011002339A (es) 2011-04-04
PL2331210T3 (pl) 2014-12-31
IL237392B (en) 2019-08-29
JP2019131578A (ja) 2019-08-08
IL237391A (en) 2017-12-31
IL237392A0 (en) 2015-04-30
HUE043278T2 (hu) 2019-08-28
PE20142371A1 (es) 2015-02-04
CN102159284B (zh) 2015-12-09
IL211135A0 (en) 2011-04-28
PE20110291A1 (es) 2011-06-04
KR101730924B1 (ko) 2017-04-27
CY1121492T1 (el) 2020-05-29
HRP20140663T1 (hr) 2014-10-10
JP2012501986A (ja) 2012-01-26
CA2735857A1 (en) 2010-03-11
ZA201101449B (en) 2011-10-26
ES2513394T3 (es) 2014-10-27
AU2018202879A1 (en) 2018-05-17
KR20110057144A (ko) 2011-05-31
EP2331210A2 (en) 2011-06-15
IL237391A0 (en) 2015-04-30
WO2010025931A2 (en) 2010-03-11
CN105520924B (zh) 2019-04-09
KR20170048602A (ko) 2017-05-08
WO2010025931A3 (en) 2010-06-17
ES2719900T3 (es) 2019-07-16
JP2015096530A (ja) 2015-05-21
PE20142357A1 (es) 2015-02-04
PE20142372A1 (es) 2015-02-04
AR073361A1 (es) 2010-11-03
BRPI0920521A2 (pt) 2018-01-16
AU2016203053A1 (en) 2016-06-02
KR20160086981A (ko) 2016-07-20
CN105520924A (zh) 2016-04-27
JP2017071636A (ja) 2017-04-13
HRP20190500T1 (hr) 2019-08-09
IL211135A (en) 2017-09-28
CN102159284A (zh) 2011-08-17
US20100063148A1 (en) 2010-03-11
SI2735338T1 (sl) 2019-04-30
EP2331210B1 (en) 2014-07-09
CO6382142A2 (es) 2012-02-15
SI2331210T1 (sl) 2014-10-30
PT2331210E (pt) 2014-08-25
DK2735338T3 (en) 2019-04-23
CL2011000317A1 (es) 2011-06-17
JP5731387B2 (ja) 2015-06-10
KR101641519B1 (ko) 2016-07-21
DK2331210T3 (da) 2014-08-11
PT2735338T (pt) 2019-05-24
EP2735338B1 (en) 2019-02-06
AU2016203053B2 (en) 2018-01-25
KR101851120B1 (ko) 2018-04-23
LT2735338T (lt) 2019-04-10
AR117613A2 (es) 2021-08-18
HK1159011A1 (en) 2012-07-27

Similar Documents

Publication Publication Date Title
AR117613A2 (es) Combinación farmacéutica
ECSP19047259A (es) Combinación farmacéutica para el tratamiento del dolor
CR20150326A (es) Inhibidores de autotaxina
UY32926A (es) Compuestos como antagonistas de los receptores de ácido lisofosfatídico
CO6551683A2 (es) Tratamiento para trastornos gastrointestinales
ECSP17013617A (es) “combinación farmacéutica que comprende 3-(3-dimetilamino-1-etil-2-metil-propil)-fenol y nsaid”
GT201200004A (es) Imidazoles fusionados y composiciones que los contienen para el tratamiento de enfermedades parasitarias, como por ejemplo malaria
NI201000164A (es) Hidroximetil pirrolidinas como agonistas del receptor adrenérgico beta 3.
MX362693B (es) Composición para el cuidado oral para tratar y/o prevenir afecciones causadas por microorganismos, usando un dispositivo oral de luz.
CL2011001331A1 (es) Clorhidrato de nalmefeno dihidratado; métodos para su preparación; composición farmacéutica que lo comprende; y uso para el tratamiento del alcoholismo.
ECSP13013012A (es) Análogos del ácido epoxieicosatrienoicos y métodos de preparación
BR112012013164A2 (pt) composições farmacêuticas para o estímulo de células-tronco
MX2013000694A (es) Vitamina c y vitamina k libre de cromo, y composiciones de estas para tratar un estado o enfermedad en las que interviene nfkb.
AR086395A1 (es) Envase para el tratamiento de patologias
AR077987A1 (es) Combinacion farmaceutica que comprende 6-dimetilaminometil-1-(3-metoxifenil)-ciclohexano-1,3-diol o 6-dimetilaminometil-1-(3-hidroxifenil)-ciclohexano-1,3-diol y un antiepileptico
CO6341550A2 (es) Combinacion farmaceutica que contiene el 6 - dimetilaminometil - 1 - (3-metoxi-fenil) - ciclohexano - 1,3 - diol y un nsaid.
PA8797801A1 (es) Uso de n-fenilamidas de acido 2-sulfonilaminobenzoico sustituidas con sulfonilo en el tratamiento del dolor
ECSP11010876A (es) Combinación farmacéutica que contiene el 6-dimetilaminometil-1-(3-metoxi-fenil)-ciclohexano-1,3-diol y paracetamol
ECSP099734A (es) Composición farmaceutica que comprende la combinación de un agente antiinflamatorio no esteroideo y un agente anticonvulsivante
DOP2013000004A (es) Agentes terapeuticos 976
GT201400115A (es) Combinación farmacéutica antineurítica y composición
ES2485540B1 (es) Compuestos útiles en el tratamiento de la aciduría metilmalónica
GT201400093A (es) Composición con un inhibidor de la bomba de protones y un antagonista h2